APLIF (Appili Therapeutics) YoY EPS Growth: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Appili Therapeutics YoY EPS Growth?

Appili Therapeutics APLIF YoY EPS Growth is 0.00% as of Mar. 2026. The stock has 2 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Appili Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2026 was 0.00%.

Appili Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $-0.01.

Appili Therapeutics YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Appili Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Appili Therapeutics YoY EPS Growth Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only -57.07 80.67 62.07 36.36 -57.14

Appili Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.00 0.00 0.00 -133.33 0.00

Appili Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Appili Therapeutics's YoY EPS Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EPS Growth (A: Mar. 2026 )
=(Earnings per Share (Diluted) (A: Mar. 2026 )-Earnings per Share (Diluted) (A: Mar. 2025 ))/ | Earnings per Share (Diluted) (A: Mar. 2025 ) |
=(-0.022--0.014)/ | -0.014 |
=-57.14 %

Appili Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EPS Growth (Q: Mar. 2026 )
=(Earnings per Share (Diluted) (Q: Mar. 2026 )-Earnings per Share (Diluted) (Q: Mar. 2025 )) / | Earnings per Share (Diluted) (Q: Mar. 2025 )) |
=(-0.007-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 0.00% mean?
Appili Therapeutics (APLIF) has a YoY EPS Growth of 0.00% as of Mar. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Appili Therapeutics and its competitors.
Is Appili Therapeutics' YoY EPS Growth too high?
Appili Therapeutics' current YoY EPS Growth is 0.00%.
How does Appili Therapeutics' YoY EPS Growth compare to VRTX and REGN?
Appili Therapeutics' YoY EPS Growth of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Appili Therapeutics and its competitors. Appili Therapeutics's current YoY EPS Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Appili Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Appili Therapeutics (APLIF) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 9.2% below its estimated fair value. The current YoY EPS Growth is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Appili Therapeutics (APLIF), the current YoY EPS Growth is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Appili Therapeutics Business Description

Other Exchanges APLI:Canada
Address 1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.